A kind of mofs nano drug carrier coated with red blood cell membrane and its preparation method and application

Abstract

The invention discloses a red blood cell membrane-coated MOFs nano-medicine carrier and its preparation method and application. The MOFs nano-medicine carrier includes MOFs nanoparticles and red blood cell membranes. The pores of the MOFs nanoparticles are loaded with boric acid. The MOFs Nanoparticles are wrapped with red blood cell membranes. The MOFs nanomedicine carrier is synthesized by hydrothermal method, with mild reaction conditions, high synthesis efficiency, uniform particle size, good monodispersity, high drug loading capacity, good fluorescence imaging ability and high biological Compatibility, can be used as anti-tumor drug carrier.

Description

technical field [0001] The invention belongs to the fields of chemistry and biomedicine, and in particular relates to a red blood cell membrane-coated MOFs nano drug carrier and a preparation method and application thereof. Background technique [0002] Although the treatment methods of cancer are constantly improving, the treatment based on anticancer drugs is still the main means of clinical cancer diagnosis and treatment. At present, the active ingredients of many drugs are unstable under physiological conditions, have low solubility, and have large toxic and side effects. Many anti-cancer drugs are not as effective as expected and can cause irreversible damage to normal tissues. Therefore, many anticancer drugs are not suitable for direct administration, and it is necessary to use appropriate drug carriers to deliver drugs in various tissues and cells, so as to reduce the number of administrations, optimize the course of treatment, reduce drug side effects and patient pa...

AI Technical Summary

Problems solved by technology

At present, although studies on porphyrin MOFs as drug carriers have shown that these materials are already at the pre-clinical level, in the application field of drug delivery, traditional MOFs still have deficiencies, such as: (1) The toxicity evaluation of MOFs materials is controversial. Bioaffinity metals and organic ligands cannot fully guarantee the safety of materials; (2) The targeting and functionality are insufficient. For drug carriers, in addition to the ability to load drugs, the targeting and Diagnostic ability is the key to realize the integration of diagnosis and treatment, which is helpful to formulate treatment plan rationally

Images